bmiMD Review

bmiMD operates the consumer platform and describes itself as a direct-to-consumer telehealth technology service rather than a medical practice or pharmacy. Licensed independent clinicians determine whether treatment is appropriate, and independent pharmacies dispense prescriptions. Current terms identify Medccm, Inc. dba bmiMD as the platform operator.

The public flow is asynchronous. A shopper chooses a program, completes a three-to-five-minute health intake, and enters payment information. bmiMD says the card is authorized at checkout but captured only after clinician approval. A licensed provider generally reviews the case within 24 to 72 hours and may ask follow-up questions or request recent laboratory results. If the clinician declines treatment, the authorization is released.

The normalized weight-management section contains compounded semaglutide injection, compounded tirzepatide injection, and metformin ER tablets. bmiMD also markets semaglutide and tirzepatide microdose programs at the same standard totals. Those are dosing protocols under the same active ingredients and injection routes, so they do not become separate comparison cards.

The normalized longevity section contains compounded sermorelin, NAD+, and glutathione as subcutaneous injections. Sermorelin tablets, sermorelin nasal spray, and NAD+ nasal spray remain in the editorial narrative because the current catalog records cover the subcutaneous formulations. MIC+B12 and naltrexone, bupropion, and vitamin B6 remain editorial-only because the exact multi-ingredient formulas have no reusable catalog match.

Compounded semaglutide costs $159 for one month, $447 for three months, $774 for six months, or $1,428 for twelve months. The provider-labeled monthly rates are $159, $149, $129, and $119. Their unweighted mean is $139, displayed as Avg. $139/mo.

Compounded tirzepatide costs $249 for one month, $687 for three months, $1,134 for six months, or $2,148 for twelve months. The provider-labeled monthly rates are $249, $229, $189, and $179. Their unweighted mean is $211.50, displayed as Avg. $212/mo.

Metformin ER costs $55 for one month or $111 for three months. The two effective monthly rates average $46. A separate shop surface has shown a lower starting figure, so the card uses the complete product-page terms and records the conflicting headline rather than treating it as a standard plan.

Sermorelin injection costs $139 for one month, $357 for three months, or $594 for six months. The effective rates of $139, $119, and $99 average $119 per month. The injection page specifies approximately 30 injections from one 5 mL vial at 2 mg/mL, an injection kit, and provider messaging. The prescribed dose and administration instructions remain clinician-specific.

NAD+ injection and glutathione injection each use standard totals of $159 for one month, $447 for three months, $774 for six months, and $1,428 for twelve months. Each produces a $139 plan-level monthly average. Nasal pricing and transient lower shop-page references are excluded from the injection cards.

The one-month label does not mean a calendar-month billing schedule. Current help says monthly subscriptions renew every 28 days from the initial purchase date. Three, six, and twelve-month plans are charged upfront and renew for the same cycle at the period end. Multi-month orders may ship one vial at a time. Klarna or Afterpay may divide the payment, but financing does not reduce the contractual commitment.

Cancellation applies prospectively. A member can pause or cancel from the portal before the next billing date, and bmiMD recommends allowing at least 48 business hours. Once a payment has processed and the order has entered pharmacy fulfillment, it cannot be canceled or refunded. Canceling a multi-month plan does not produce a refund for the unused prepaid portion.

Initial-order refunds have a narrow window. If the clinician does not approve treatment, bmiMD says the patient is not charged. After approval but before pharmacy processing, an initial cancellation may incur a non-refundable $50 medical and administrative fee. Pharmacy processing typically begins within 24 hours of approval, and all sales become final once processing starts.

Official pages conflict on damaged, missing, or incorrect shipments. Current help says to contact support within 48 hours, while the refund policy says 24 hours. The safer consumer deadline is 24 hours. An address generally cannot be changed after the pharmacy receives the order or tracking is created, and bmiMD does not promise replacement for an address entered incorrectly by the patient.

Shipping is included and tracking is provided. Injectable shipments use insulated packaging and ice packs. Current pages variously describe two to four days after approval, three to five business days, or five to seven business days total. The review treats two to seven business days as a provider-stated range, not a guarantee.

Current help says bmiMD does not accept insurance, Medicare, Medicaid, FSA, or HSA at checkout. A paid invoice can be requested for reimbursement submission, but reimbursement depends on the insurer or plan administrator. An older bmiMD article said FSA and HSA cards were accepted, so the review uses the newer guidance and records the conflict.

Availability is product-specific. Several current treatment pages state all-50-state access, while MIC+B12 excludes California and South Carolina and sermorelin tablets exclude South Carolina. Older GLP-1 pages and current general statements are not fully consistent, so the review does not assign one nationwide rule to the entire catalog.

The terms name Precision Compounding Pharmacy but also state that the pharmacy depends on state and patient circumstances and that another pharmacy may be requested. The current help center refers more generally to licensed pharmacy partners. The prescription and medication label, not the marketing page, identify the pharmacy responsible for an individual order.

FDA states that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. Section 503A pharmacies are state licensed and primarily overseen by state boards; they are not FDA-licensed outsourcing facilities. bmiMD's references to an FDA 503A licensed partner pharmacy and FDA-licensed sources are inaccurate, so this review uses FDA's statutory distinctions instead.

FDA's current GLP-1 guidance says semaglutide and tirzepatide are no longer on the shortage list and raises concerns about unapproved versions, dosing errors, salt forms, and adverse events. A compounded preparation may be considered only when a licensed prescriber determines it is appropriate for an identified patient under applicable law. A bmiMD product page does not establish that patient-specific basis.

Clinical questions go through the patient portal, where bmiMD states that a provider generally responds within 24 to 72 hours. Order, shipping, and billing questions go to orders@bmimd.com. No current public phone line or service hours were verified, and these channels are not emergency care.

The Katalys bmiMD application is pending under offer 1332. The recorded payout is $150 for a GLP-1 sale and $100 for another eligible treatment, with a discovery EPC of $11.52. No issued tracking URL or verified affiliate-compatible customer promotion is available. Commercial terms affected queue order only and did not affect the score or findings.